ZAK is providing services in the entire area of clinical research development in Europe. We are ready to share with you more than 20 years of experience in clinical research and regulatory affairs in order to ensure the success of your projects!
If you are looking for professional support, we will find solutions which meet your interest, budget and internal resources!
Ingrid Hochmayer, M.Sc.
Patrizia Kahl-Rainer, D.Sc.
Proxy Holder/Head of Clinical Operations/Finance & Controlling Manager
Éva Ráczkevy, MD
Head of Hungarian Representation/Co-Managing Director Hungary
Barbara Markhardt, M.Sc.
Clinical Trial Regulatory Specialist/Project Manager
Barbara Haas, M.Sc.
Clinical Research Specialist/Medical Writer
Georg Franz, M.Sc.
Regulatory Affairs Manager/Senior Clinical Research Associate
ZAK SERVICES BLOG
7 Reasons your Clinical Trial isn't recruiting enough patients
As many as 85% of clinical trials fail to recruit and retain enough patients in order to meet their enrollment timeline. In total, 80% of trials fail to finish on time, despite the fact that a good third of a study budget often goes into patient recruitment and retention. (1)
Gemeinsames Mittagessen als Teil der Unternehmenskultur von ZAK
Montag Suppen- oder Kalte-Platte-Tag, Dienstag Nudeltag, Mittwoch Spaghetti-Tag, Donnerstag Fischtag… so oder so ähnlich geht es bei uns, bei ZAK, Woche für Woche in einer gewissen Regelmäßigkeit oder Vorhersehbarkeit betreffend Mittagessen her.
Honour for ZAK CEO | Dr. Jean-Jacques Chirikdjian
On November 9th the golden badge of honour of the state of Vienna was awarded to our CEO for special efforts at the Viennese town hall. In the course of an official ceremony Dr. Jean-Jacques Chirikdjian has received the honour for his contribution as a researcher, developer and business owner.
Opportunities for Small/Medium Enterprises
Over the past decade, the rising costs of R&D combined with profit pressures, increased regulatory requirements, need for innovation in R&D process, resulted in changing of outsourcing strategy of all big pharmaceutical companies to strategic partnerships. The majority of companies indicated a preference to engage global CROs for exclusive partnerships rather than mid-sized or niche CROs.